Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2Q3VY
|
|||
| Drug Name |
Tepoditamab
|
|||
| Synonyms |
MCLA-117
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Acute myelogenous leukaemia [ICD-11: 2A41; ICD-10: C92.2] | Phase 1 | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloid inhibitory C-type lectin-like receptor (CD371) | Target Info | . | [2] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | . | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03038230) MCLA-117 in Acute Myelogenous Leukemia. U.S. National Institutes of Health. | |||
| REF 2 | MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019 Jul;19(7):721-733. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.